Gordon Cook, MB ChB, PhD, FRCP(Glas), FRCPath, Leeds Teaching Hospitals NHS Trust, Leeds, UK, briefly discusses considerations for frailty adapted treatment approaches in multiple myeloma, highlighting the importance of the Myeloma XIV trial (FiTNEss; NCT03720041). This interview took place at the 20th International Myeloma Society (IMS) Annual Meeting, held in Athens, Greece.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.